Concord Medical Services (CCM) has released an update.
Concord Medical Services Holdings Limited reported a decline in its financial performance for the first half of 2024, with total net revenues dropping by 23.1% and a net loss doubling from the previous year. Despite the downturn, the company remains optimistic, bolstered by its Guangzhou subsidiary securing a license for proton therapy equipment, which is expected to enhance revenue and growth in the oncology sector.
For further insights into CCM stock, check out TipRanks’ Stock Analysis page.
